Growth hormone (GH) therapy in GH-deficient patients, the plasma factor VIII-von Willebrand factor complex, and capillary fragility. A double-blind, placebo-controlled crossover study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

However, limited information is available on these features in GH-deficient patients.

The researchers therefore examined, in a double-blind, placebo-controlled crossover design, the effects of 4 months' replacement therapy with biosynthetic human GH in 22 GH-deficient adults on circulating haemostatic parameters and capillary fragility.

Who Took Part

By PubMed's age tags, the people studied were teenagers and adults, both men and women.

How the Study Was Run

The researchers set it up as a double-blind, placebo-controlled and crossover study.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Capillary Fragility, Erythrocyte Indices, Factor VIII, Growth Hormone, Hematocrit, Insulin and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1990 (Scandinavian journal of clinical and laboratory investigation), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.